CADTH Canadian Drug Expert Committee recommendation: Tofacinitib (Xeljanz) indication: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to either conventional UC therapy or a tumor necrosis factor-alpha inhibitor (TNFi)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be reimbursed for the treatment of adult patients with moderately to severely active UC with an inadequate response, loss of response, or intolerance to either conventional UCtherapy or a TNFi

Bibliographic Details

Corporate Author:	CADTH Canadian Drug Expert Committee
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2019, March 2019
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK572050
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa